Clinical trials: Multiple Sclerosis
Multiple Sclerosis
A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan
This study aims to evaluate the real-world persistence and adherence to ofatumumab (OMB) treatment in adult patients with relapsing multiple sclerosis (RMS).
- Trial name
- NCT07821411
- Where
- Switzerland
- Volunteers
- 5,000 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments.
- Trial name
- NCT04956744
- Testing
- IMS001
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImStem Biotechnology
Multiple Sclerosis
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
- Trial name
- NCT00336557
- Testing
- NAbs testing
- Where
- 49 sites in United States
- Volunteers
- 1,230 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01006265
- Testing
- ACT-128800 Dose 1, ACT-128800 Dose 2, ACT-128800 Dose 3
- Where
- 115 sites in United States, Australia and 21 more
- Volunteers
- 464 people
- Sponsor
- Actelion
Multiple Sclerosis, Relapsing-Remitting
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition
This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments…
- Trial name
- NCT02598167
- Where
- 18 sites in Spain
- Volunteers
- 223 people
- Sponsor
- Hoffmann-La Roche
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Multiple Sclerosis
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease associated with central nervous system (CNS) demyelination and subsequent axonal degeneration. Multiple sclerosis exhibits an unpredictable and variable clinical course.
- Trial name
- NCT01517282
- Testing
- MOR103
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 32 people
- Sponsor
- MorphoSys AG
Relapsing-remitting Multiple Sclerosis
Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
The purpose of this study is to evaluate the proportion of patients who demonstrate no medical need to discontinue therapy among DMT-naïve patients with relapsing forms of multiple sclerosis after 1 year of treatment with Rebif…
- Trial name
- PROTRACT (NCT02823951)
- Testing
- Rebif, Tecfidera
- Where
- 23 sites in United States, Canada
- Volunteers
- 479 people
- Sponsor
- IMS HEALTH GmbH & Co. OHG
Multiple Sclerosis
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims…
- Trial name
- NCT07566988
- Where
- United States
- Volunteers
- 2,604 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple…
- Trial name
- RECYCLINE (NCT01134627)
- Testing
- Minocycline
- Where
- Denmark
- Volunteers
- 305 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non-relapsing Secondary Progressive Multiple Sclerosis
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic…
- Trial name
- HERCULES (NCT04411641)
- Testing
- Tolebrutinib
- Where
- 306 sites in United States, Argentina and 29 more
- Volunteers
- 1,131 people
- Sponsor
- Sanofi
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
This is an open-label, randomized, multicenter, comparative, and parallel-group study comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting multiple sclerosis (MS).
- Trial name
- NCT00292266
- Testing
- Rebif®, Avonex®
- Volunteers
- 677 people
- Sponsor
- EMD Serono
Multiple Sclerosis Spasticity
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
- Trial name
- MSS (NCT06782490)
- Testing
- BMS-986368
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Celgene
Multiple Sclerosis
A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
The primary objective of this study is to better understand the pathophysiological background of end-of-dose symptoms (EOD) and thereby determine the percentage of participants who develop EOD under natalizumab (NTZ) as an…
- Trial name
- SATURATE-MS (NCT05701423)
- Testing
- Natalizumab
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Biogen
Multiple Sclerosis
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
This is a study aimed to characterize [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of [18F]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple…
- Trial name
- NCT01428505
- Testing
- [18F]PBR111
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Lung Cancer
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics.
- Conditions
- Multiple Sclerosis, Lung Cancer, Breast Cancer
- Trial name
- NCT06136923
- Testing
- CT-100-D-004-A, CT-100-D-004-B
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Click Therapeutics, Inc.
Relapsing Multiple Sclerosis (RMS)
Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study
This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine…
- Trial name
- CHRONOS (NCT06486779)
- Testing
- Ofatumumab
- Where
- 15 sites in Greece
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
The main purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic profile of two intravenous infusions of BIIB033 administered two weeks apart in subjects with MS.
- Trial name
- NCT01244139
- Testing
- BIIB033
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Biogen
Relapsing Forms of Multiple Sclerosis
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program.
- Trial name
- NCT01201356
- Testing
- Fingolimod
- Where
- 458 sites in United States, Argentina and 36 more
- Volunteers
- 4,125 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
- Trial name
- FILAXOS (NCT06551519)
- Testing
- ofatumumab, DMT category 1
- Where
- 82 sites in Germany
- Volunteers
- 519 people
- Sponsor
- Novartis Pharmaceuticals